Posts tagged Hydros-TA
Leerink downgrades Carbylan to market perform

Leerink Partners has downgraded Carbylan Therapeutics (NASDAQ:CBYL) to “market perform” from “outperform” and slashed its price target to $1.83 from $15 after the company reported a disappointing Phase 3 readout for Hydros-TA in the COR 1.1 trial. The shares were down 46% to $1.33 in after-market trading on Monday.

The company’s lead program, Hydros-TA, is a hyaluronic acid (HA) plus steroid combination product for the treatment of symptoms associated with knee osteoarthritis.

Read More